Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Entrada Therapeutics Inc (TRDA)

Entrada Therapeutics Inc (TRDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 288,063
  • Shares Outstanding, K 37,953
  • Annual Sales, $ 210,780 K
  • Annual Income, $ 65,630 K
  • EBIT $ 4 M
  • EBITDA $ -2 M
  • 60-Month Beta -0.06
  • Price/Sales 1.41
  • Price/Cash Flow 4.95
  • Price/Book 0.71

Options Overview Details

View History
  • Implied Volatility 290.95% ( +33.33%)
  • Historical Volatility 59.69%
  • IV Percentile 99%
  • IV Rank 100.00%
  • IV High 290.95% on 06/13/25
  • IV Low 42.89% on 06/21/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 9
  • Volume Avg (30-Day) 8
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 323
  • Open Int (30-Day) 310

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.86
  • Number of Estimates 3
  • High Estimate -0.72
  • Low Estimate -0.98
  • Prior Year 1.55
  • Growth Rate Est. (year over year) -155.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.42 +2.29%
on 05/23/25
8.75 -13.26%
on 05/14/25
-1.11 (-12.76%)
since 05/13/25
3-Month
7.10 +6.90%
on 04/09/25
11.36 -33.19%
on 03/17/25
-3.23 (-29.85%)
since 03/13/25
52-Week
7.10 +6.90%
on 04/09/25
21.79 -65.17%
on 12/09/24
-8.86 (-53.86%)
since 06/13/24

Most Recent Stories

More News
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

TRDA : 7.59 (-3.31%)
BIIB : 130.65 (-1.25%)
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TRDA : 7.59 (-3.31%)
Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

TRDA : 7.59 (-3.31%)
Entrada Therapeutics Reports First Quarter 2025 Financial Results

TRDA : 7.59 (-3.31%)
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

TRDA : 7.59 (-3.31%)
Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

TRDA : 7.59 (-3.31%)
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

TRDA : 7.59 (-3.31%)
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy

TRDA : 7.59 (-3.31%)
Best Momentum Stocks to Buy for December 30th

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, December 30th:CoreCard Corporation CCRD: This technology solutions and processing services company...

NRXP : 3.54 (+2.91%)
TRDA : 7.59 (-3.31%)
CCRD : 28.30 (-4.17%)
New Strong Buy Stocks for December 30th

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:CoreCard Corporation CCRD: This technology solutions and processing services company has seen the Zacks Consensus Estimate for its...

APPN : 29.46 (-3.69%)
USNA : 29.55 (-0.77%)
NRXP : 3.54 (+2.91%)
TRDA : 7.59 (-3.31%)
CCRD : 28.30 (-4.17%)

Business Summary

Entrada Therapeutics Inc. is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles(TM) to engage intracellular targets. Entrada Therapeutics Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 8.04
2nd Resistance Point 7.92
1st Resistance Point 7.75
Last Price 7.59
1st Support Level 7.47
2nd Support Level 7.35
3rd Support Level 7.19

See More

52-Week High 21.79
Fibonacci 61.8% 16.18
Fibonacci 50% 14.45
Fibonacci 38.2% 12.71
Last Price 7.59
52-Week Low 7.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar